TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2010 Health Care Conference (Business Wire) BURLINGTON, N.C.----Laboratory Corporation of America® Holdings today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch Health Care Conference in New York, NY. us.rd.yahoo.com |
Vivus: Options Trade for FDA Panel Decision Stock Yid submits:On July 15th the FDA Panel will be reviewing the weight loss drug made by Vivus (VVUS). If the panel gives a positive review of the drug then the stock can jump 50%, if they give the weight loss drug a negative review then the stock can drop 50%. Basically we are talking about VVUS being eiter $5 of $15 on July 16th.Complete Story » seekingalpha.com |
FDA Questions Anticlotting Drug In a review posted on its website Monday, the FDA questioned the effectiveness of ticagrelor, a proposed anticlotting drug developed by AstraZeneca. online.wsj.com |
Cell Therapeutics to Challenge FDA Decision Zacks.com submits: Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate, pixantrone. The candidate is being developed for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who have not responded to other treatment options.In April 2010, the FDA denied approval to pixantrone, and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone.Complete Story » seekingalpha.com |
Sanofi-Aventis to Lay Off 1,700 U.S. Employees Sanofi-Aventis said it is eliminating 1,700 jobs in its U.S. pharmaceutical business in a restructuring triggered by generic competition and other factors. online.wsj.com |